ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,676.05
-0.34%
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs Yen
153.055
0.00%
Brent Oil
82.765
0.00%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. AVEO Pharmaceuticals Inc (AVEO)

  7. AVEO Pharmaceuticals Inc (AVEO) ニュース

AVEO

AVEO Pharmaceuticals (AVEO)

AVEO Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:AVEO
日付受信時刻ニュースソース見出しコード企業名
2024/03/2904 : 22GlobeNewswire Inc.CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeNASDAQ:AVEOAVEO Pharmaceuticals Inc
2024/03/2521 : 10GlobeNewswire Inc.AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeNASDAQ:AVEOAVEO Pharmaceuticals Inc
2024/02/0622 : 10GlobeNewswire Inc.AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The OncologistNASDAQ:AVEOAVEO Pharmaceuticals Inc
2024/01/1621 : 30GlobeNewswire Inc.AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/3106 : 08Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2420 : 07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2420 : 07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2420 : 07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2007 : 20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2007 : 17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2007 : 17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2007 : 16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2007 : 16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2007 : 05Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 47Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 46Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 44Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 43Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 42Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 40Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 40Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 38Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/2006 : 35GlobeNewswire Inc.LG Chem Completes Acquisition of AVEO OncologyNASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/1822 : 41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2023/01/0606 : 59Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2022/12/2406 : 02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2022/12/2306 : 47Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2022/12/0223 : 07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2022/12/0223 : 05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
2022/11/2522 : 09Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AVEO

最近閲覧した銘柄

CCOM
US100
US Tech 100
CCOM
SILVER
SILVER
NYSE
XOM
Exxon Mobil
NASDAQ
GOOGL
Alphabet
NASDAQ
TSLA
Tesla
FX
USDJPY
US Dollar vs Yen
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
BAC
Bank of America
USOTC
ADDYY
Adidas (QX)
USOTC
RHHBY
Roche (QX)
USOTC
BASFY
BASF (QX)
COIN
BTCUSD
Bitcoin
NYSE
AXP
American Express
NASDAQ
AMZN
Amazon.com
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有